Aspire Biopharma Enters Material Definitive Agreement

Ticker: ASBPW · Form: 8-K · Filed: Apr 30, 2025 · CIK: 1847345

Sentiment: neutral

Topics: material-definitive-agreement, corporate-actions

TL;DR

Aspire Biopharma just signed a big deal, filing an 8-K on it.

AI Summary

Aspire Biopharma Holdings, Inc. entered into a material definitive agreement on April 24, 2025. The filing also includes financial statements and exhibits related to this agreement. The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp.

Why It Matters

This filing indicates a significant new development for Aspire Biopharma, potentially impacting its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided text.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Aspire Biopharma Holdings, Inc.?

The provided text states that Aspire Biopharma Holdings, Inc. entered into a material definitive agreement on April 24, 2025, but does not specify the details of the agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on April 24, 2025.

What were the former names of Aspire Biopharma Holdings, Inc.?

Aspire Biopharma Holdings, Inc. was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp.

What is the Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc.?

The SIC code for Aspire Biopharma Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

In which state was Aspire Biopharma Holdings, Inc. incorporated?

Aspire Biopharma Holdings, Inc. was incorporated in Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing